PLX · Protalix BioTherapeutics, Inc.
$2.71
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$219.15M
Shares
80.57M
Volume · Oct 5
984.07K
Avg daily vol (3M)
716.33K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.71
Open$2.70
Day$2.64–2.72
52W close$1.67–3.15
Avg vol 30d766K
Short int2.9M · 3.6% float · 3.8d
Short vol41%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 5 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+15.8%
Trailing year
Short interest
3.6%
Latest settlement · 3.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 12, 2026
Q2 FY26
TL;DR. Protalix reported Q2 2026 revenues from selling goods of $19.8 million (up $4.4 million YoY) and reaffirmed full-year 2026 total revenue guidance of $78.0–$83.0 million, while swinging to $3.8 million net income and highlighting Elfabrio's U.S. patent term extension and South Korea approval.
Bullish
- + Q2 product revenues rose $4.4 million YoY to $19.8 million driven by Elfabrio sales.
- + Year-to-date revenue more than doubled to $53.6 million and the company achieved $22.1 million YTD net income.
- + Q2 net income increased to $3.8 million ($0.05/share) versus $164,000 in Q2 2025.
- + Company reaffirmed full-year 2026 revenue guidance of $78.0–$83.0 million, including the $25.0 million Chiesi milestone.
- + Balance sheet of $40.7 million cash/short-term deposits with no debt or warrants supports operations and the PRX-115 Phase 2 trial.
Bearish
- − Q2 cost of revenues rose 32% YoY to $7.8 million, outpacing revenue growth and pressuring gross margin.
- − Management warned of lumpiness in Elfabrio partner purchases driven by Chiesi inventory management rather than underlying demand signals.
- − License and R&D services revenue is set to decline materially, with the company expecting minimal such revenues going forward.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+16%
above
Price vs 50-day avg
+7%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
70%
mid-range
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+18%
trailing
YTD return
+51%
this year
Relative strength
+6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.57% of float · ▼ -9.1% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 3-yr high, broad support
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
−1%
Y/Y
Gross margin
8%
expanding
EPS growth
−300%
Y/Y
Free cash flow
$-13.6M
Valuation
P/E 11.3
in line
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Total revenue
· 2026
$78M – $83M
prior FY $52.74M
midpoint +52.6% Y/Y
Fabio revenues excluding milestones
· 2026
$33M – $35M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+16%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
70%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.57% of float · ▼ -9.1% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 70%
Range high $3
vs 200-day avg +16%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and short-term bank deposits | $40.7M | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLX
this stock
Protalix BioTherapeutics, Inc.
|
$219.15M | +50.6% | -1.2% | 11.3 | 3.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLX | -0.4% | +3.4% | +18.3% | -1.8% | +50.6% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -0.2% | +3.9% | +6.2% | -2.7% | +37.7% |